Answers are grounded in this paper and cite their sources.
OBJECTIVES: AA amyloidosis is the most severe complication of familial Mediterranean fever (FMF), primarily involving the kidneys. This study evaluates renal outcomes in FMF patients treated with canakinumab, one of the anti-IL-1 agents employed when the patient is colchicine intolerant or resistant. METHODS: Patients' data were collected in the International Autoinflammatory Disease Alliance (AIDA) Network registry dedicated to monogenic autoinflammatory diseases (MAIDs). RESULTS: Overall, 158 FMF patients received canakinumab (CAN) for a mean of 45.2±34.5 months (590.9 patient-years). Amyloidosis was present in 14 patients (8.9%) at baseline, with one new case during follow-up. Proteinuria was observed in 24 cases (15.2%) at baseline, with one new and two recurrent cases. Mean 24-hour proteinuria significantly decreased from 2932±2473 mg to 1593±1135 mg at 12 months and 1149±1125 mg at last assessment (p = 0.005). Reduction correlated with treatment with CAN duration (rho=0.77) and baseline proteinuria (rho=0.91). Linear regression showed a decline of 34.95 mg/24 h per month, greater in the first 12 months, but still significant till the assessment. Kidney failure occurred in 5 (3.2%) at baseline and one new case during treatment. Overall, 28 patients were treated in monotherapy with CAN, and did not develop any kidney complications in a median follow-up period of 24 (3-121, IQR 51) months. CONCLUSIONS: Canakinumab is effective in FMF patients with kidney involvement, inducing significant and progressive reductions in 24-hour proteinuria in both the short and long term. It seems as well to prevent new renal complications in most patients, also when used as monotherapy.
No takes yet. Share an insight, caveat, or question.
Vitale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: